IPO

The IPO was open for subscription from January 20 to January 22, with a price band of INR 118 to INR 124 per share.

The Bengaluru-based company had submitted its Draft Red Herring Prospectus (DRHP) through the confidential route in September last year.

Mitra founder Abhishek Kaushik will become Promoter and Managing Director of the merged entity.

In 2025, 20 venture-backed startups went public, nine new unicorns emerged, taking India's ecosystem to USD 419 billion, with over 1,540 unicorns overall, including 28 profitable companies.

The IPO will open for public subscription on January 20.

The IPO will open for public subscription on January 13 and close on January 16.

The IPO is expected to be launched towards the end of the year.

Proceeds from the fresh issue are expected to be used mainly to strengthen the capital base of Kissht's non-banking financial company (NBFC) arm, Si Creva Capital Services.

Premji Invest and Accel are set to post strong gains from Amagi's IPO, with Premji Invest eyeing nearly 14x returns and Accel expected to benefit by about 41%.

The company has also filed its draft red herring prospectus (DRHP) with the market regulator SEBI.

Considering the developments, Zepto might be aiming for a stock market listing in 2026, with its rivals Swiggy and Eternal both listed on the BSE and the NSE.

The move comes as Zepto prepares to confidentially file its draft red herring prospectus (DRHP) on December 26.

IPO opens on December 23, 2025, closes on December 26, 2025

Quadria invested in NephroPlus in May 2024 to support its expansion across Asia and other regions.

Global and domestic institutions increasingly treat consumer-tech IPOs as part of their long-duration growth bucket, comparable to specialty retail or branded consumer platforms rather than traditional loss-making tech ventures. Retail investors, however, are engaging with offerings such as this in a structurally different risk environment.

According to regulatory filings, the company submitted its IPO papers through the confidential pre-filing route.

The offering will include a fresh issue of equity shares worth INR 1,100 crore, while existing shareholders and co-founders will sell shares worth INR 1,242.35 crore through an offer for sale.

LEAP India and Eldorado Agritech, along with Molbio Diagnostics, Foodlink F&B Holdings India, and Technocraft Ventures, have all received the approval.

The Initial Public Offering (IPO) of the Bengaluru-based Wakefit Innovations Limited's share sale experienced 0.36 times subscription end of day 2. The Ahmedabad-based Corona Remedies has launched its own IPO, with the issue booked 9.2 times so far, and GMP signals 24 per cent listing gains with strong interest from retail investors and NIIs.

Key anchor investors included major domestic and global institutions such as Ashoka Whiteoak, HDFC Life, Bajaj Life, Prudential Hong Kong, 360 One, Steadview Capital, Amundi and several leading mutual funds.

The bid/offer will open on Monday, December 8, 2025 and close on Wednesday, December 10, 2025, with an anchor investor bidding window scheduled for Friday, December 5, 2025.